A Multi-center Phase II Study of Trastuzumab Biosimilar (SB3) in Combination With Ramucirumab and Paclitaxel in HER2 Positive Metastatic Gastric Cancer Patients
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Ramucirumab (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 17 Sep 2019 Planned initiation date changed from 31 Jan 2019 to 30 Sep 2019.
- 17 Sep 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Dec 2018 New trial record